Last updated on June 2017

A Two-part Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies


Brief description of study

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies

Clinical Study Identifier: NCT01830010

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novartis Pharmaceuticals

Novartis Investigative Site
Paris, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Pessac cedex, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Freiburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Hamburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Jena, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Koeln, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Regensburg, Germany
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Basel, Switzerland
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Zürich, Switzerland
  Connect »